Wave Life Sciences USA, Inc.

Contributing Author

Recent Articles by Wave Life Sciences USA, Inc.

Dec-09	Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants WVE GlobeNewswire
Dec-08	Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants WVE GlobeNewswire
Dec-08	Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss WVE GlobeNewswire
Dec-07	Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 WVE GlobeNewswire
Nov-10	Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update WVE GlobeNewswire
Nov-07	Wave Life Sciences to Present at Upcoming Investor Conferences WVE GlobeNewswire
Nov-04	Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek 2025 WVE GlobeNewswire
Nov-04	Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025 WVE GlobeNewswire
Oct-29	Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day WVE GlobeNewswire
Oct-29	Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day WVE GlobeNewswire
Sep-18	Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences WVE GlobeNewswire
Sep-03	Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency WVE GlobeNewswire
Jul-30	Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE GlobeNewswire
Jul-23	Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 WVE GlobeNewswire
Jun-20	Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions WVE GlobeNewswire
May-29	Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference WVE GlobeNewswire
May-28	Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer WVE GlobeNewswire
May-08	Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update WVE GlobeNewswire
May-01	Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 WVE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.